| Effect | Decrease |
| Trial Design | Double blind |
| Trial Length | 6+ Months |
| Number of Subjects | 50 |
| Sex | Both Genders |
| Age Range | 1-6, 7-12, 13-17 |
| Body Types | Average |
In children and adolescents, CoQ10 supplementation reduced migraine and headache frequency significantly during weeks 1-4 of the trial, to a greater extent than placebo. In the latter portions of the trial, there were no differences between CoQ10 and Placebo.
CoQ10 was administered at 100mg daily.
